SCHEMBL20152029

SCHEMBL20152029

Cc1cccc(NC(=O)C(C)I)c1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.61
KMT2A Q03164 3/20 0.56
MEN1 O00255 2/20 0.56
RXFP1 Q9HBX9 1/20 0.56
SMN1; SMN2 Q16637 3/20 0.52
KCNK3 O14649 1/20 0.51
KCNH2 Q12809 1/20 0.51
KCNK9 Q9NPC2 1/20 0.51
PKM P14618 1/20 0.51
HPGD P15428 1/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
ALDH1A1 P00352 2/20 0.50
CYP1A2 P05177 1/20 0.50
SAE1 Q9UBE0 1/20 0.50
UBA2 Q9UBT2 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
GAA P10253 1/20 0.50
TP53 P04637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2735680 0.86 HSD17B10 (0.65) HSD17B10KMT2AMEN1RXFP1SMN1; SMN2
SCHEMBL30729659 0.84 HSD17B10 (0.62) HSD17B10KMT2AMEN1RXFP1SMN1; SMN2
SCHEMBL20152024 0.83 ALDH1A1 (0.61) HSD17B10KMT2AMEN1SMN1; SMN2PKM
SCHEMBL26464127 0.83 HSD17B10 (0.61) HSD17B10KMT2AMEN1RXFP1SMN1; SMN2
SCHEMBL12812735 0.83 HSD17B10 (0.61) HSD17B10KMT2AMEN1RXFP1SMN1; SMN2
SCHEMBL4820385 0.83 HSD17B10 (0.61) HSD17B10KMT2AMEN1RXFP1SMN1; SMN2
SCHEMBL4003494 0.83 HSD17B10 (0.61) HSD17B10KMT2AMEN1RXFP1SMN1; SMN2
SCHEMBL6429391 0.81 HSD17B10 (0.64) HSD17B10KMT2AMEN1RXFP1SMN1; SMN2
SCHEMBL13255714 0.81 HSD17B10 (0.59) HSD17B10KMT2AMEN1RXFP1SMN1; SMN2
SCHEMBL17896778 0.81 HSD17B10 (0.62) HSD17B10KMT2AMEN1RXFP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10369140-B2 Aryl dihydropyridinones and piperidinone MGAT2 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2019-08-06 US disclosed
US-20180133198-A1 ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180133198-A1 ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS DGAT2, MGAT2, MGAT1 HSD17B10 153/4885KMT2A 155/4885MEN1 2323/4885
US-10369140-B2 Aryl dihydropyridinones and piperidinone MGAT2 inhibitors DGAT2, MGAT2, MGAT1 HSD17B10 153/4885KMT2A 155/4885MEN1 2323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.